People · Operator
Named in public records as an officer, director or promoter · active 2022–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Syncromune, Inc. | — | Biotechnology | Series C | $65.0M | $385.7M | 2022 |
Eamonn J. Hobbs at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Eamonn J. Hobbs on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jeffrey J. Kraws | 1 | 3 |
| Jeffrey L. Cleland | 1 | 3 |
| Charles J. Link | 1 | 2 |
| Douglas G. Watson | 1 | 2 |
| Joseph C. Maroon | 1 | 2 |
| Gregory J. Champion | 1 | 1 |
| Norman L. Schwartz | 1 | 1 |
| Kerri-Ann L. Millar | 1 | 1 |
| Agustin J. Gago | 1 | 1 |
| Joseph J. Gerardi | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.